Vol. 36. No. 3


While various medical specialties treat eczema patients, care for these patients is largely fragmented and disorganized. Moreover, standardized treatment protocols that incorporate upcoming eczema therapies and emerging guidelines have yet to be established. Thus, there is both a need and an opportunity to equip clinicians to succeed in this novel and changing era of eczema care. The National Eczema Association’s (NEA) strategic plan—developed through extensive discussions with patients who have atopic dermatitis and their caregivers, industry, and providers representing different specialties—called for the creation of an interdisciplinary coalition to steer this initiative. The Coalition United for Better Eczema Care (CUBE-C) is a network of cross-specialty leaders working to help construct an educational curriculum based on standards of effective treatment and disease management.

Atopic dermatitis: phototherapy and systemic therapy

Dawn Marie Davis, MD | Jenna Borok, BS | Jeremy Udkoff, MA | Jonathan Spergel, PhD | Peter Lio, MD
Few studies have compared head-to-head efficacy of the different immunosuppressant therapies such as cyclosporine, methotrexate, azathioprine and mycophenolate mofetil.

Atopic dermatitis: emerging therapies

Eric Simpson, MD, MCR | Jenna Borok, BS | Jeremy Udkoff, MA | Lawrence F. Eichenfield, MD | Lisa Beck, MD | Wynnis Tom, MD
We review newly-approved and emerging topical and systemic medications for AD as well as novel early life approaches to preventing the disease onset.